Lyell Immunopharma (LYEL) FCF Margin Growth (3y) (2023 - 2026)

Lyell Immunopharma (LYEL) FCF Margin Growth (3y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) FCF Margin Growth (3y) (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -1,272.00
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn -2,228.00
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 9,545.00
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -7.75 Mn
7 Royalty Pharma 33.72 Bn 35.84 Bn - -3,088.00
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 4,612.00
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 14,060.00
10 Lyell Immunopharma 326.39 Mn 326.39 Mn - -70.34 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 -70.34 Mn
Mar 31, 2026 -185.65 Mn
Dec 31, 2025 -55.05 Mn
Sep 30, 2025 158.70 Mn
Jun 30, 2025 -43.38 Mn
Mar 31, 2025 -77.55 Mn
Dec 31, 2024 -42.37 Mn
Sep 30, 2024 -10.33 Mn
Jun 30, 2024 -29.22 Mn
Mar 31, 2024 -139.96 Mn
Dec 31, 2023 -33.06 Mn
Sep 30, 2023 -13.77 Mn